Endogenous melatonin profiles in asymptomatic inflammatory bowel disease.

Patients with inflammatory bowel disease (IBD) complain of poor sleep [1,2], specifically of prolonged sleep latency, repeated awakenings, and poorer sleep quality than healthy controls, even in remission [1]. Possible contributors to this poor sleep include abdominal pain, diarrhea, bathroom trips, stress about future flare-ups, conditioned insomnia, altered immune function, and/or systemic inflammation [1,2]. Circadian disruption can also disturb sleep [3] and is linked to increased incidence of ulcers [4], colorectal cancer [5], and IBD [6]. We recently showed that chronic circadian disruption significantly exacerbates chemically induced colitis in mice, leading to greater weight loss, intestinal tissue injury, and colonic inflammation [7]. To date, circadian state has not been assessed in IBD patients. The gold standard measure of the circadian clock in humans is the melatonin rhythm [8]. This pilot study had two aims: (1) to determine if there was any circadian disruption in asymptomatic IBD patients (by examining the relationship between the timing of the melatonin rhythm and sleep) and (2) to determine if circulating melatonin levels were abnormally low, potentially contributing to the chronic inflammation and poor sleep in IBD. This is the first report of comprehensively measured melatonin rhythms in IBD patients. Four patients (two males, 22–39 years), three with Crohn’s disease and one with ulcerative colitis (clinical and histologically proven) participated. All were symptom free for at least 1 month prior. Patients were of normal weight and were not taking melatonin supplements, sleep aids, or nonsteriodal anti-inflammatory drugs (prescribed medications listed in Figure 1). All patients were nonsmokers and passed a drug screen, except Patient 2 who quit smoking at enrollment (at his own volition) and tested positive for marijuana. All patients had not worked night shifts or crossed time zones in the previous month. The patients wore wrist monitors (Actiwatch-L, Phillips) and followed their habitual sleep schedules for 8–9 days at home before their dim light salivary endogenous melatonin profiles were assessed as per standard procedures [9]. The protocol was approved by the Rush University Medical Center Institutional Review Board and was in accordance with the Declaration of Helsinki. Figure 1 Salivary melatonin profiles of four patients with asymptomatic inflammatory bowel disease. Each patient’s habitual sleep times are represented by a black rectangle. Patients stopped consuming alcohol and caffeine three days before the melatonin ... The wrist actigraphy data revealed that three patients had longer wake time after sleep onset than eight age and sex matched controls recruited online [10] (Table I). The patients’ sleep onset latency was significantly longer and sleep efficiency significantly lower than controls (Table I, both p < 0.05). These data are consistent with previous reports of poor sleep in patients with IBD. Table I The sleep parameters of the four IBD patients and eight matched control subjects during 7 days of baseline sleep. Three of the four patients had circadian rhythms in their melatonin secretion. The variability in the timing and amount of melatonin secreted was similar to a large sample of healthy controls [9]. The patients’ various medications did not abolish the melatonin rhythm in three patients. The lack of circadian rhythm in Patient 2’s melatonin secretion may have been due to his recent smoking and marijuana use. Nonetheless, the results indicate that the circadian rhythm in melatonin excretion can be abnormal in some patients with IBD and this should be studied in a larger cohort.